The psychedelics treatment developer reported a net loss of $34.7 million for the quarter ended Dec. 31, 2024, widening from a $23.8 million loss a year earlier.
CMPS earnings call for the period ending December 31, 2024.
Kennedy has previously advocated for decriminalizing psychedelics for therapeutic use, citing his son’s positive experience with the hallucinogenic brew ayahuasca.
Don't jump in without doing some research first.
Markets sent a clear message Friday following President-elect Donald Trump’s nomination of Robert F. Kennedy Jr. to head the Department of Health and Human Services (HHS). Vaccine stocks took a nosedive,...
CMPS earnings call for the period ending September 30, 2024.
CMPS earnings call for the period ending June 30, 2024.
Down 84% from all-time highs, Compass Pathways is a beaten-down biotech stock that trades at a massive discount to consensus price target estimates in 2024.
Nothing is going wrong, but one of its peers just hit a serious snag.
Regulators were not impressed by one company's petition for approval.